{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ludwig LM"],"funding":["U.S. Department of Health &amp; Human Services | NIH | National Institute of General Medical Sciences","Jill and John Svoboda; The Rizzo Family Foundation","NCI NIH HHS","AbbVie-University of Chicago Collaborative; The Comer Developmental Board; Jill and John Svoboda; The Rizzo Family Foundation; Donald and Catherine Kleinmuntz","NIGMS NIH HHS"],"pagination":["1005"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8551340"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(11)"],"pubmed_abstract":["BH3 mimetics are increasingly used as anti-cancer therapeutics either alone or in conjunction with other chemotherapies. However, mounting evidence has also demonstrated that BH3 mimetics modulate varied amounts of apoptotic signaling in healthy immune populations. In order to maximize their clinical potential, it will be essential to understand how BH3 mimetics affect discrete immune populations and to determine how BH3 mimetic pressure causes immune system adaptation. Here we focus on the BCL-2 specific inhibitor venetoclax (ABT-199) and its effects following short-term and long-term BCL-2 blockade on T cell subsets. Seven day \"short-term\" ex vivo and in vivo BCL-2 inhibition led to divergent cell death sensitivity patterns in CD8<sup>+</sup> T cells, CD4<sup>+</sup> T cells, and Tregs r"],"journal":["Cell death & disease"],"pubmed_title":["Venetoclax imparts distinct cell death sensitivity and adaptivity patterns in T cells."],"pmcid":["PMC8551340"],"funding_grant_id":["P01 CA065493","T32 CA009594","T32GM007281","T32 GM007281"],"pubmed_authors":["Banks DB","Leverson JD","Ludwig LM","Blazar BR","Hawley KM","McNerney ME","Thomas-Toth AT","LaBelle JL"],"additional_accession":[]},"is_claimable":false,"name":"Venetoclax imparts distinct cell death sensitivity and adaptivity patterns in T cells.","description":"BH3 mimetics are increasingly used as anti-cancer therapeutics either alone or in conjunction with other chemotherapies. However, mounting evidence has also demonstrated that BH3 mimetics modulate varied amounts of apoptotic signaling in healthy immune populations. In order to maximize their clinical potential, it will be essential to understand how BH3 mimetics affect discrete immune populations and to determine how BH3 mimetic pressure causes immune system adaptation. Here we focus on the BCL-2 specific inhibitor venetoclax (ABT-199) and its effects following short-term and long-term BCL-2 blockade on T cell subsets. Seven day \"short-term\" ex vivo and in vivo BCL-2 inhibition led to divergent cell death sensitivity patterns in CD8<sup>+</sup> T cells, CD4<sup>+</sup> T cells, and Tregs r","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Oct","modification":"2025-04-19T15:34:07.114Z","creation":"2025-04-19T15:34:07.114Z"},"accession":"S-EPMC8551340","cross_references":{"pubmed":["34707089"],"doi":["10.1038/s41419-021-04285-4"]}}